Posizolid

Posizolid (AZD2563), an oxazolidinone antibiotic, is developed by AstraZeneca for the study of bacterial infections. Posizolid shows very good anti-mycobacterial activity[1].

Product Specifications

CAS Number

[252260-02-9]

Product Name Alternative

AZD2563; AZD5847

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Antibiotic

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/posizolid.html

Solubility

10 mM in DMSO

Smiles

O=C1O[C@@H](COC2=NOC=C2)CN1C3=CC(F)=C(C4=CCN(C([C@@H](O)CO)=O)CC4)C(F)=C3

Molecular Formula

C21H21F2N3O7

Molecular Weight

465.40

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Kumar D, et al. The anti-tuberculosis agents under development and the challenges ahead. Future Med Chem. 2015;7 (15) :1981-2003.|[2]Baum SE, et al. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46 (9) :3094-3095.|[3]Balasubramanian V, et al. Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2014;58 (7) :4185-4190.